Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Summit Therapeutics (SMMT)
NASDAQ:SMMT
Holding SMMT?
Track your performance easily
SMMT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.79 - $33.89
Previous Close$21.77
Volume1.88M
Average Volume (3M)5.11M
Market Cap
$16.05B
Enterprise Value$15.84B
Total Cash (Recent Filing)$325.47M
Total Debt (Recent Filing)$108.70M
Price to Earnings (P/E)―
Beta-2.45
Next Earnings
Mar 13, 2025EPS Estimate
-$0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding737,448,146
10 Day Avg. Volume2,256,895
30 Day Avg. Volume5,112,548
Standard Deviation0.63
R-Squared0.00585
Alpha0.13
Financial Highlights & Ratios
Price to Book (P/B)36.90
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-130.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-137.56
Forecast
1Y Price Target
$34.75Price Target Upside67.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Summit Therapeutics News
PremiumCompany Announcements
Summit Therapeutics Advances NSCLC Trials and Strengthens Financials
PremiumCompany Announcements
Summit Therapeutics Advances Ivonescimab for Lung Cancer
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressSummit announced that the company has completed enrollment in the Phase 3 (HARMONi) trial of ivonescimab, which is a major milestone for advancing the treatment of specific lung cancer patients.
Comparative EfficacyIvonescimab is clearly better than Keytruda in NSCLC, with slam dunks in each of four important disease subtypes.
Regulatory AdvancementsThe FDA granted ivonescimab Fast Track designation, which expedites regulatory interactions and allows for rolling review of Biologic License Applications.
Bears Say
Competitive AnalysisBNT327 demonstrated superior performance with a higher objective response rate of 100% compared to 83% for ivonescimab in the PD-L1 >10% group.
Financial PerformanceThe expected share price return is only 0.8%, indicating limited upside potential for investors.
Market OpportunitiesThe data are uncontrolled with very limited participants, leading to a high-risk estimation with only a 25% probability of success and a 30% peak market share as the most optimistic assessment.
---
Ownership Overview
80.14% Insiders
2.60% Mutual Funds
0.12% Other Institutional Investors
14.61% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SMMT FAQ
What was Summit Therapeutics’s price range in the past 12 months?
Summit Therapeutics lowest stock price was $1.79 and its highest was $33.89 in the past 12 months.
What is Summit Therapeutics’s market cap?
Currently, no data Available
When is Summit Therapeutics’s upcoming earnings report date?
Summit Therapeutics’s upcoming earnings report date is Mar 13, 2025 which is in 112 days.
How were Summit Therapeutics’s earnings last quarter?
Summit Therapeutics released its earnings results on Oct 30, 2024. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.067 by $0.017.
Is Summit Therapeutics overvalued?
According to Wall Street analysts Summit Therapeutics’s price is currently Undervalued.
Does Summit Therapeutics pay dividends?
Summit Therapeutics does not currently pay dividends.
What is Summit Therapeutics’s EPS estimate?
Summit Therapeutics’s EPS estimate is -$0.08.
How many shares outstanding does Summit Therapeutics have?
Summit Therapeutics has 737,448,100 shares outstanding.
What happened to Summit Therapeutics’s price movement after its last earnings report?
Summit Therapeutics reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.067. Following the earnings report the stock price went down -14.567%.
Which hedge fund is a major shareholder of Summit Therapeutics?
Among the largest hedge funds holding Summit Therapeutics’s share is Baker Bros Advisors LP. It holds Summit Therapeutics’s shares valued at 181M.
---
Summit Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.75 (67.39% Upside)
$34.75 (67.39% Upside)
Blogger Sentiment
Bullish
SMMT Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 23.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $498.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 13.9%
Last 30 Days ▲ 29.6%
Last 30 Days ▲ 29.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1042.78%
12-Months-Change
Fundamentals
Return on Equity
-73.22%
Trailing 12-Months
Asset Growth
130.16%
Trailing 12-Months
Company Description
Summit Therapeutics
Summit Therapeutics Plc operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company operates through the Drug Development segment, which covers its research and development activities carried out by the Group. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom.
---
SMMT Earnings Call
Q3 2024
0:00 / 0:00
---
SMMT Stock 12 Month Forecast
Average Price Target
$34.75
▲(67.39% Upside)
Technical Analysis
Best Analysts Covering SMMT
1 Year
1 Year Success Rate
6/6 ratings generated profit
1 Year Average Return
+255.37%
reiterated a buy rating 22 days ago
Copying Bradley Canino's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +255.37% per trade.
---